PARP Inhibitor Maintains QoL in Recurrent Ovarian Cancer

Submitted by admin5 on Mon, 09/11/2017 - 15:38

Administration of a poly ADP-ribose polymerase (PARP) inhibitor to patients with recurrent ovarian cancer after an initial response to platinum-based chemotherapy helps maintain quality of life (QoL) during treatment, according to a study presented at the European Society for Medical Oncology 2017 Congress (Madrid, Spain; September 8-12, 2017).

A previous trial (ENGOT-0V16/NOVA) demonstrated that the PARP inhibitor niraparib induces significant response and prolonged progression-free survival (PFS) in patients with recurrent ovarian cancer following complete or partial response. However, further research is needed to assess patient-reported outcomes after niraparib in this population.

Amit M Oza, MD, FRPCPC, department of medical oncology and hematology, Princess Margaret Hospital, University of Toronto, and colleagues conducted a study to analyze patient-reported outcomes—after maintenance therapy with niraparib—and their association with QoL. The Functional Assessment of Cancer Therapy-Ovarian Cancer Symptoms Index and the European Quality of Life Scale 5-Dimensions (EQ-5D-5L) were utilized to evaluate individual patient-reported symptoms in both niraparib and placebo groups.

Researchers created a mixed-effect growth-curve that adjusted for three stratification factors and baseline demographics to reflect the correlations between the patient-reported outcomes scores and treatment for each measure. Subsequent health status and patient-reported associations were evaluated by a cross-sectional analysis of adjusted EQ-5D-5L health utility index scores.


Related Content

ICER Releases Value Assessment of PARP Inhibitors for Ovarian Cancer

PARP Inhibitors Crucial to the Future of Ovarian Cancer Treatment


Results of the analysis showed that no significant difference existed in patient-reported outcomes scores between the niraparib and placebo groups. Adjusted health utility index scores were comparable at baseline in both groups, but average adjusted health utility index scores prior to progression were higher in the niraparib group (0.812 vs 0.803 in the germline BRCA-mutation cohort; 0.845 vs 0.828 in the non-germline BRCA-mutation cohort, respectively).

In their concluding remarks, researchers concluded that patients’ overall health utility was not negatively impacted by hematologic toxicities. Therefore, niraparib maintenance therapy can successfully contribute to sustained QoL, they concluded.—Zachary Bessette